Search

Displaying results 3221 - 3230 of 7502 in total
  1. Drug

    Talopram

    go.drugbank.com/drugs/DB09190
    Experimental

    Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.

  2. Drug

    Demegestone

    go.drugbank.com/drugs/DB13857
    Experimental

    Demegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.

  3. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like [nivolumab] or CTLA-4 inhibitors like [ipilimumab] - to

  4. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer … Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.

  5. Drug

    Tetrahydrofolic acid

    go.drugbank.com/drugs/DB00116
    InvestigationalNutraceutical

    Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. … It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.

  6. Drug

    Mexiletine

    go.drugbank.com/drugs/DB00379
    ApprovedInvestigational

    Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

  7. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    Firocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine. … Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox.

    Categories: Anti-Inflammatory Agents, Non-Steroidal
  8. Drug

    OPC-14523

    go.drugbank.com/drugs/DB05422
    Experimental

    OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

  9. Drug

    Phenylbutazone

    go.drugbank.com/drugs/DB00812
    ApprovedVet approvedWithdrawn

    Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)

    Synonyms: 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine, 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedioneCategories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  10. Drug

    Carboplatin

    go.drugbank.com/drugs/DB00958
    ApprovedInvestigational

    [A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]